EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy in Locally Advanced Cervical Carcinoma: A Narrative Review

Claire Meynard, Emmanuel Fardeau, Tiphaine Lambert iD, Sophie Guillerm, Diane Jornet iD, Laurent Quero iD, Christophe Hennequin

Cancers · 29.04.2026 · 18 (9) · 1409

DOI: 10.3390/cancers18091409 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.04.2026. Verfasst von Claire Meynard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Hôpital Saint-Louis, AP-HP, Université Paris-Cité, 75010 Paris, France. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of locally advanced cervical cancer is based on concomitant cisplatin-based chemoradiotherapy followed by brachytherapy. The quality of this treatment is essential to optimize results. In particular, intensity-modulated radiotherapy followed by image-guided brachytherapy achieves 90% local control regardless of the stage of the disease. More recently, several randomized trials have changed the management of these tumors: The INTERLACE trial evaluated the benefits of neoadjuvant chemotherapy with carboplatin and paclitaxel and demonstrated a survival benefit for this approach. This trial has been the subject of considerable criticism. The KEYNOTE A.18 trial evaluated the addition of pembrolizumab to standard treatment: an improvement in overall survival was demonstrated for patients with stage III-IV disease (FIGO 2014 classification). The CALLA trial, which evaluated the addition of durvalumab, was negative. This review summarizes the biological rationale for this immunotherapy, its results, and the quality criteria for chemoradiotherapy. It describes the various trials in detail, puts their results into context, and discusses the relevance of this new treatment based on the patients’ baseline characteristics. Based on this critical analysis, patients with stage III-IVA cervical cancer (FIGO 2014 classification) should receive, in addition to standard chemoradiotherapy, concomitant treatment with pembrolizumab followed by two years of maintenance therapy.

Schlagwörter

Stichwörter der Autor:innen

cervical cancerimmunotherapyradiotherapy

Autor:innen und Institutionen

  • Radiation Oncology Department, Hôpital Saint-Louis, AP-HP, Université Paris-Cité, 75010 Paris, France.
  • Medical Oncology Department, Hôpital Saint-Louis, AP-HP, Université Paris-Cité, 75010 Paris, France.

ORCID-Profile: Tiphaine Lambert, Diane Jornet, Laurent Quero

Zitieren

APA

Meynard, C., Fardeau, E., Lambert, T., Guillerm, S., Jornet, D., Quero, L., & Hennequin, C. (2026). Immunotherapy in Locally Advanced Cervical Carcinoma: A Narrative Review. Cancers, 18(9), 1409. https://doi.org/10.3390/cancers18091409

Vancouver

Meynard C, Fardeau E, Lambert T, Guillerm S, Jornet D, Quero L, et al. Immunotherapy in Locally Advanced Cervical Carcinoma: A Narrative Review. Cancers. 2026;18(9):1409. doi:10.3390/cancers18091409

BibTeX
@article{Meynard2026,
  author = {Meynard, Claire and Fardeau, Emmanuel and Lambert, Tiphaine and Guillerm, Sophie and Jornet, Diane and Quero, Laurent and Hennequin, Christophe},
  title = {Immunotherapy in Locally Advanced Cervical Carcinoma: A Narrative Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1409},
  doi = {10.3390/cancers18091409}
}
Kostenlos starten →